| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8242173 | International Journal of Radiation Oncology*Biology*Physics | 2007 | 10 Pages |
Abstract
Conclusions: A proton radiotherapy schedule consisting of 5 fractions of 5 CGE as part of neoadjuvant therapy for adenocarcinoma of the pancreas seems dosimetrically feasible, providing excellent target volume coverage, dose homogeneity, and normal tissue sparing. Hypofractionated proton radiotherapy in this setting merits Phase I clinical trial investigation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Kevin R. M.D., Ph.D., Lisa A. M.D., Judith C.M.D., Elizabeth M. M.S., Brian M. M.D., Harvey J. M.D., Ph.D., Carlos M.D., David P. M.D., Thomas F. M.D., Theodore S. M.D.,